Meloxicam Decreases the Migration and Invasion of CF41.Mg Canine Mammary Carcinoma Cells

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Aug 8

PMID 28781660

Citations 10

Authors

Maria P Iturriaga

Rodolfo Paredes

Jose I Arias

Cristian G Torres

Affiliations

Soon will be listed here.

Abstract

Cyclooxygenase (COX)-2 expression is positively correlated with malignant features in canine mammary carcinomas. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX activity and may therefore possess anticancer effects. Meloxicam is an NSAID that is widely used in human and veterinary medicine. High concentrations of meloxicam have been reported to be antitumorigenic ; however, the effect of meloxicam at concentrations that are equivalent to those that can be obtained remains unknown. In the current study, the effects of low-dose meloxicam (0.25 µg/ml) on CF41.Mg canine mammary carcinoma cells were evaluated. The effects on cell proliferation, apoptosis, cell migration and invasion, in addition to the expression of different molecules associated with tumor invasiveness were analyzed. No effect on cell viability and apoptosis were observed. However, cell migration and invasion were significantly reduced following treatment with meloxicam. MMP-2 expression and activity were similarly reduced, explaining the impaired cell invasion. In addition, β-catenin expression was downregulated, while its phosphorylation increased. These results indicate that 0.25 µg/ml meloxicam reduces cell migration and invasion, in part through modulating MMP-2 and β-catenin expression. Additional studies are required to elucidate the mechanism associated with the anti-invasive effect of meloxicam on CF41.Mg cells. The results of the present study suggest that meloxicam has a potential adjunctive therapeutic application, which could be useful in controlling the invasion and metastasis of canine mammary carcinomas.

Citing Articles

Contribution of non-steroidal anti-inflammatory drugs to breast cancer treatment: and studies.

Ferreira T, Faustino-Rocha A, Gaspar V, Medeiros R, Mano J, Oliveira P Vet World. 2024; 17(5):1052-1072.

PMID: 38911075 PMC: 11188899. DOI: 10.14202/vetworld.2024.1052-1072.

Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies.

Nosalova N, Huniadi M, Hornakova L, Valencakova A, Hornak S, Nagoos K Int J Mol Sci. 2024; 25(5).

PMID: 38474142 PMC: 10931591. DOI: 10.3390/ijms25052891.

Antitumor Effects of Esculetin, a Natural Coumarin Derivative, against Canine Mammary Gland Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis.

Choi J, Yoo M, Park S, Seol J Vet Sci. 2023; 10(2).

PMID: 36851388 PMC: 9961495. DOI: 10.3390/vetsci10020084.

First study on the immunohistochemical expression of cyclooxygenase-2 and clinicopathological association in canine hepatoid gland neoplasms.

Chantawong P, Mamom T, Tangtrongsup S, Chitsanoor S, Boonsriroj H Vet World. 2022; 15(10):2432-2441.

PMID: 36425143 PMC: 9682401. DOI: 10.14202/vetworld.2022.2432-2441.

CircRNA Expression Profiles in Canine Mammary Tumours.

Zhu Y, Lu B, Wu J, Li S, Jia K Vet Sci. 2022; 9(5).

PMID: 35622733 PMC: 9145538. DOI: 10.3390/vetsci9050205.

References

Lee K, Kim Y, Yoo H, Lee S, Park J, Kim H . Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood-brain barrier. Anticancer Res. 2011; 31(12):4307-13. View

Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, Huber C . Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos. 1998; 26(6):576-84. View

Schrey M, Patel K . Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer. 1995; 72(6):1412-9. PMC: 2034098. DOI: 10.1038/bjc.1995.523. View

Knottenbelt C, Chambers G, Gault E, Argyle D . The in vitro effects of piroxicam and meloxicam on canine cell lines. J Small Anim Pract. 2006; 47(1):14-20. DOI: 10.1111/j.1748-5827.2006.00006.x. View

Zhong S, Zhang X, Chen L, Ma T, Tang J, Zhao J . Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies. Breast Cancer Res Treat. 2015; 150(1):199-207. DOI: 10.1007/s10549-015-3300-z. View

Dore M, Lanthier I, Sirois J . Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol. 2003; 40(2):207-12. DOI: 10.1354/vp.40-2-207. View

Sonzogni-Desautels K, Knapp D, Sartin E, Dore M . Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours. Vet Comp Oncol. 2011; 9(3):161-71. DOI: 10.1111/j.1476-5829.2010.00242.x. View

Lavalle G, de Campos C, Bertagnolli A, Cassali G . Canine malignant mammary gland neoplasms with advanced clinical staging treated with carboplatin and cyclooxygenase inhibitors. In Vivo. 2012; 26(3):375-9. View

Roarty K, Rosen J . Wnt and mammary stem cells: hormones cannot fly wingless. Curr Opin Pharmacol. 2010; 10(6):643-9. PMC: 2981611. DOI: 10.1016/j.coph.2010.07.004. View

10.

De Monte C, Carradori S, Gentili A, Mollica A, Trisciuoglio D, Supuran C . Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer. Curr Med Chem. 2015; 22(24):2812-8. DOI: 10.2174/0929867322666150716113501. View

11.

Saito T, Dai T, Asano R . The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumor cells. Oncol Lett. 2013; 5(3):1068-1074. PMC: 3576365. DOI: 10.3892/ol.2013.1124. View

12.

Luna S, Basilio A, Steagall P, Machado L, Moutinho F, Takahira R . Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen, and meloxicam in dogs. Am J Vet Res. 2007; 68(3):258-64. DOI: 10.2460/ajvr.68.3.258. View

13.

Saito T, Tamura D, Asano R . Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors. Oncol Rep. 2014; 31(4):1637-44. DOI: 10.3892/or.2014.3010. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Montoya L, Ambros L, Kreil V, Bonafine R, Albarellos G, Hallu R . A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs. Vet Res Commun. 2004; 28(5):415-28. DOI: 10.1023/b:verc.0000034995.81994.49. View

16.

Waskewich C, Blumenthal R, Li H, Stein R, Goldenberg D, Burton J . Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002; 62(7):2029-33. View

17.

Lavalle G, Bertagnolli A, Tavares W, Cassali G . Cox-2 expression in canine mammary carcinomas: correlation with angiogenesis and overall survival. Vet Pathol. 2009; 46(6):1275-80. DOI: 10.1354/vp.08-VP-0226-C-FL. View

18.

Torres C, Pino A, Sierralta W . A cyclized peptide derived from alpha fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells. Oncol Rep. 2009; 21(6):1397-404. DOI: 10.3892/or_00000367. View

19.

Queiroga F, Alves A, Pires I, Lopes C . Expression of Cox-1 and Cox-2 in canine mammary tumours. J Comp Pathol. 2007; 136(2-3):177-85. DOI: 10.1016/j.jcpa.2007.01.010. View

20.

Wolfesberger B, Hoelzl C, Walter I, Reider G, Fertl G, Thalhammer J . In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells. J Vet Pharmacol Ther. 2006; 29(1):15-23. DOI: 10.1111/j.1365-2885.2006.00704.x. View